Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: RANI

Rani Therapeutics Holdings, Inc.

Healthcare | Biotechnology

No licensed closing price on file for RANI. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (FY2025)$-0.45

Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 23:43 UTC.

What Rani Therapeutics Holdings, Inc. does

The company is a clinical-stage biotherapeutics firm developing the RaniPill capsule, a proprietary oral delivery platform designed to administer biologics and drugs without injections. The platform has two configurations: the RaniPill GO, which delivers up to a certain dose in microtablet form, and the RaniPill HC, a high-capacity version intended for larger liquid drug payloads, with Phase 1 clinical trials completed for the RaniPill GO and a Phase 1 trial initiated for a GLP-1/GLP-2 dual agonist candidate.

Summarized from Rani Therapeutics Holdings, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (FY2025)$-0.45

Revenue, margins & earnings

FY2021: net loss $8M on revenue $3M$3MFY2021FY2024: net loss $30M on revenue $1M$1MFY2024FY2025: net loss $30M on revenue $2M$2MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-09-29
  • 2026-09-29Chief Executive OfficerTax withholding-7,928$6.0K
  • 2026-09-29Chief Technical OfficerTax withholding-309$235
  • 2026-08-04DirectorDirector Stock Option (Right to Buy)Award247,200—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Rani Therapeutics Holdings, Inc. do?

The company is a clinical-stage biotherapeutics firm developing the RaniPill capsule, a proprietary oral delivery platform designed to administer biologics and drugs without injections.

When did RANI last file with the SEC?

Rani Therapeutics Holdings, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-30. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 23:43 UTC. This page is also available as JSON at /api/data?ticker=RANI and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for RANI and 5,000+ tickers.

Create a free account — keep RANI
For your agent
GET /api/data?ticker=RANI

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt